CERECOR Trademark

Trademark Overview


On Friday, May 10, 2019, a trademark application was filed for CERECOR with the United States Patent and Trademark Office. The USPTO has given the CERECOR trademark a serial number of 88424870. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, July 4, 2022. This trademark is owned by Cerecor Inc.. The CERECOR trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of disorders and diseases in or affecting the central nervous system; Pharmaceutical preparations for the treatment of the brain, central nervous system, and psychiatric and neurological diseases and disorders; Pharmaceutical preparations and substances for the prevention and treatment of major depressive disorder, mood disorder, psychosis, anxiety, epilepsy, sclerosis, porphyries, stroke, Huntington's disease, insomnia, Parkinson's disease, cognitive impairment; Pharmaceutical preparations for the treatment of ectoparasites, such as head lice; Steroids; Pharmaceutical preparations containing prednisolone for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculoskeletal system, the genitourinary system; Pharmaceutical preparations containing prednisolone for the treatment of inflammatory disorders; Pharmaceutica...
cerecor

General Information


Serial Number88424870
Word MarkCERECOR
Filing DateFriday, May 10, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, July 4, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 8, 2019

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention and treatment of disorders and diseases in or affecting the central nervous system; Pharmaceutical preparations for the treatment of the brain, central nervous system, and psychiatric and neurological diseases and disorders; Pharmaceutical preparations and substances for the prevention and treatment of major depressive disorder, mood disorder, psychosis, anxiety, epilepsy, sclerosis, porphyries, stroke, Huntington's disease, insomnia, Parkinson's disease, cognitive impairment; Pharmaceutical preparations for the treatment of ectoparasites, such as head lice; Steroids; Pharmaceutical preparations containing prednisolone for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculoskeletal system, the genitourinary system; Pharmaceutical preparations containing prednisolone for the treatment of inflammatory disorders; Pharmaceutical preparations containing prednisolone for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Medical delivery apparatus, namely, a valved holding chamber sold empty for use with metered dose inhalers; Cephalosporins; Antibiotics; Pharmaceutical preparations for the treatment of reflux, esophagitis, GERD (Gastro-Esophageal Reflux Disease), dyspepsia, heartburn, acid regurgitation, pyrosis, epigastric pain, irritative cough and dysphonia; Oral modified release, extended release, and/or sustained release pharmaceutical preparations for the drug carbinoxamine, a pharmaceutically acceptable salt thereof and/or carbinoxamine polistirex, intended for the treatment of seasonal and perennial allergic rhinitis, and other approved uses; Vitamin, mineral and fluoride preparations for human medical or nutritional uses; Nutritional preparation in the nature of nutritional supplement containing vitamins and fluoride; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral formulation of D-galactose for the treatment of phosphoglucomutase 1 (PGM1) deficiency (PGM1-CDG), oral formulation of D-mannose for the treatment of Mannose Phosphate Isomerase (MPI) deficiency (MPI-CDG), oral formulation of L-fucose for the treatment of Leukocyte Adhesion Deficiency Type II (LADII) (SLC35C1-CDG), nucleotide prodrug for the treatment of Deoxyguanosine Kinase (DGUOK) deficiency; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral formulations for the treatment of congenital disorders of glycosylation; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral nucleotide replacements for the treatment of Myelodysplastic Syndromes; Pharmaceutical preparations and substances for the treatment of neurogenic orthostatic hypotension (nOH) associated with neurodegenerative diseases such as Parkinson's Disease, Multiple Systems Atrophy, and Pure Autonomic Failure; Transmembrane AMPA receptor regulatory proteins (TARPs) for use as anticonvulsant agents and to modulate neurotransmission in patients with epilepsy; Oral neuro-selective adjunctive medications; Selective kappa opioid receptor (KOR) antagonist for the treatment of major depressive disorder (MDD) and for substance use disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, May 25, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAVALO THERAPEUTICS, INC.
Party Type21 - New Owner After Publication
Legal Entity Type03 - Corporation
AddressWAYNE, PA 19087

Party NameCerecor Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressEnglewood, CO 80112

Party NameCerecor Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressRockville, MD 20850

Trademark Events


Event DateEvent Description
Tuesday, July 5, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, July 4, 2022ABANDONMENT - NO USE STATEMENT FILED
Friday, December 3, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 1, 2021SOU EXTENSION 4 GRANTED
Wednesday, December 1, 2021SOU EXTENSION 4 FILED
Wednesday, December 1, 2021TEAS EXTENSION RECEIVED
Wednesday, September 22, 2021AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Saturday, May 22, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 20, 2021SOU EXTENSION 3 GRANTED
Thursday, May 20, 2021SOU EXTENSION 3 FILED
Thursday, May 20, 2021TEAS EXTENSION RECEIVED
Tuesday, December 8, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, December 7, 2020SOU EXTENSION 2 GRANTED
Wednesday, December 2, 2020SOU EXTENSION 2 FILED
Wednesday, December 2, 2020TEAS EXTENSION RECEIVED
Friday, June 5, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 3, 2020SOU EXTENSION 1 GRANTED
Wednesday, June 3, 2020SOU EXTENSION 1 FILED
Wednesday, June 3, 2020TEAS EXTENSION RECEIVED
Tuesday, June 2, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, June 2, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, June 2, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, June 2, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, June 2, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, June 2, 2020WITHDRAWAL OF ATTORNEY GRANTED
Tuesday, June 2, 2020TEAS WITHDRAWAL OF ATTORNEY RECEIVED
Wednesday, May 27, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, May 27, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, April 28, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, April 28, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, April 28, 2020TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Tuesday, April 28, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, April 28, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, April 28, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, December 3, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, October 8, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 8, 2019PUBLISHED FOR OPPOSITION
Wednesday, September 18, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, September 5, 2019ASSIGNED TO LIE
Monday, September 2, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, August 30, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, August 30, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, August 30, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, August 1, 2019NOTIFICATION OF PRIORITY ACTION E-MAILED
Thursday, August 1, 2019PRIORITY ACTION E-MAILED
Thursday, August 1, 2019PRIORITY ACTION WRITTEN
Thursday, July 25, 2019ASSIGNED TO EXAMINER
Saturday, May 25, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, May 14, 2019NEW APPLICATION ENTERED IN TRAM